Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03203473 · ClinicalTrials.gov registry record · Phase 2
Study of Optimized Management of Nivolumab Based on Response in Patients With Advanced RCC (OMNIVORE Study)
A Phase 2 study of Renal Cancer, sponsored by Toni Choueiri, MD.
- Active
- Registry status
- Phase 2
- Development phase
- 85
- Enrollment target
- 8
- Study locations
NCT03203473: Active Phase 2 study of Renal Cancer, sponsored by Toni Choueiri, MD.
NCT03203473 is a Phase 2 study of Renal Cancer that is active but no longer recruiting, run by Toni Choueiri, MD. The registered enrollment target is 85 participants, below the 607-participant average among 29 other Renal Cancer trials with a reported enrollment target (86% lower). The trial reports 8 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03203473, a Phase 2 study of Renal Cancer, is active but no longer recruiting, sponsored by Toni Choueiri, MD.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 85 participants
- Enrollment target
- 8
- Study locations
Study Summary
This research study is studying two drugs at different time points as a possible treatment for advanced renal cell cancer The drugs involved in this study are: Nivolumab Ipilimumab
Primary Outcome
Persistent PR or CR is defined per Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1 guidelines. Radiologic disease assessment was performed every 8 weeks after patients discontinued nivolumab induction therapy. At 1 year after nivolumab discontinuation, the percentage of patients with persistent PR and CR were reported (for Arm A only).
Conditions Studied
Interventions
- DRUG Nivolumab
- DRUG Ipilimumab
Study Locations (8)
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
- Dana Farber Cancer Institute - Boston
California
- University of California, San Diego Moores Cancer Center - La Jolla
Illinois
- University of Chicago Medical Center - Chicago
North Carolina
- University of North Carolina at Chapel Hill - Chapel Hill
Rhode Island
- Lifespan Comprehensve Cancer Center - Providence
Utah
- University of Utah, Huntsman Cancer Center - Salt Lake City
Wisconsin
- Unviersity of Wisconsin Carbone Cancer Center - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 85 participants |
| Start Date | 2017-10-26 |
| Est. Completion | 2026-06-28 |
| Phase | Phase 2 |
What the registry record for NCT03203473 still lists
NCT03203473 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 85 participants, a relatively small participant target, below the 607-participant average among 29 other Renal Cancer trials with a reported enrollment target (86% lower).
The record links to 1 condition, with Renal Cancer appearing as the primary indexed condition, and to 2 interventions - of which Nivolumab is the first listed.
NCT03203473 lists 8 locations in 7 states (Massachusetts, California, Illinois).
Frequently Asked Questions
What is clinical trial NCT03203473 about?
NCT03203473 is a clinical study titled "Study of Optimized Management of Nivolumab Based on Response in Patients With Advanced RCC (OMNIVORE Study)". This research study is studying two drugs at different time points as a possible treatment for advanced renal cell cancer The drugs involved in this study are: Nivolumab Ipilimumab
What is the current status of trial NCT03203473?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 85 participants. The study started on 2017-10-26. Estimated completion is 2026-06-28.
What conditions does trial NCT03203473 study?
This clinical trial studies the following conditions: Renal Cancer.
What interventions are being tested in trial NCT03203473?
The interventions under investigation include: Nivolumab (DRUG), Ipilimumab (DRUG).
Who is sponsoring clinical trial NCT03203473?
This trial is sponsored by Toni Choueiri, MD, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03203473 being conducted?
This trial has 8 study locations across California, Illinois, Massachusetts, North Carolina, Rhode Island. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Renal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03203473's enrollment target sits among peer trials
85 20th of 29 higher than 10 of 29 other Renal Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Renal Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
RECRUITING · Phase 2
-
NSAID Use After Robotic Partial Nephrectomy
RECRUITING · Phase 2
-
Neoadjuvant Pembrolizumab and Axitinib in Renal Cell Carcinoma With Inferior Vena Cava Tumor Thrombus
RECRUITING · Phase 2
-
A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint Inhibitors
ACTIVE NOT RECRUITING · Phase 2
-
9-ING-41 in Patients with Advanced Cancers
ACTIVE NOT RECRUITING · Phase 2
-
A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003)
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00842283 · 85 participants
Role of Angiogenesis in Dermatologic Diseases: A Potential Therapeutic Target
- NCT02133196 · 85 participants · Phase 2
T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer
- NCT03823144 · 85 participants · NA
Intravital Microscopy in Human Solid Tumors
- NCT03875638 · 85 participants · Phase 2
Treating Hyperexcitability in AD With Levetiracetam
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI